Executive Committee – Taj Pharma Group

In order for Taj Pharma Group to have executive Business Structure; the Board defines the executive committee as a “group of executives and executive directors appointed to act on behalf of, and within the powers granted to them by, the board of directors.

Position Name, year of birth
Corporate Executive Committee  
Group CEO Mr. A.K.SINGH
General Manager Mr. Subhash C Jaiswal) (1948)
Chief Financial Officer Dr. Hussain (1953)
Research Mr.Mohan Khetan (1947)        
Corporate Services and Human Resources Dr. Pushpit Patel (1954)
Permanent Participants  
Head Global Pharma Development Mr. Burmal Strewart (1945)
Head Pharma Partnering Mr.Mohanty Shreedrhan(1967)
Head of Taj Pharmaceuticals
Diagnostics’ business area
Diabetes Care
Mr.A.R.Jamwal (1955)
Head Global Corporate Communications Mr.Shantanu Kumar Singh
President and CEO Dr. Osman Shau (1947)
Secretary to the Corporate Executive Committee  
Head Chairman’s Officer Mr. A.K. Kohli (1978)

22 August 2019

Taj Pharma Group

A dream for new world Anchored in India and committed to its traditional values of leadership with trust, the Taj Pharma Group is spreading its footprint globally through excellence and innovation.

Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the export market remains the priority. For others it is developing a robust presence in domestic markets given growing population of India. And then there are Group companies, a small but growing number, that have global ambitions; additionally, synchronizing these ventures to cater Indian market remains a priority for growth.

Exports from India remain the cornerstone of the Taj Pharma Group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in Spain, Germany, Middle East, Africa, Russia, and CIS Countries), joint ventures (in Sri Lanka, UK) and acquisitions.

While individual Taj companies have differing geographical imperatives, the Taj Pharma Group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are UK, Sri Lanka, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.

Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited, sums up the Taj group’s efforts to internationalize its operations thus: “We hope that a several years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business conglomerate that is at home in the world, carrying the same sense of trust that we do today.” We have already progressed on such efforts by our current presence in more than 40 countries.

About Taj Pharma

Taj Pharmaceuticals is the global leader in generics and one of the India’s top ten pharmaceutical companies. Taj Pharma India play a leading role in therapeutic areas such as cancer, virology and transplantation. The combined strengths of Taj Pharma generics and pharmaceuticals businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients’ needs. Taj Pharmaceutical’s products and services address the entire healthcare spectrum, from screening for genetic risk factors, to preventing, diagnosing and treating disease, and monitoring the treatment response.

Taj Pharma India delivers a unique contribution to better healthcare. Taj Pharma India aim to reduce suffering and improve health and quality of life of people all around the world. At Taj Pharmaceuticals, Taj Pharma India have pursued this mission with patience, dedication, imagination and skill, for over a century. Taj Pharma vision is to develop targeted medicines and diagnostic tools that combine to offer patients, physicians and payers better, safer, more cost-effective healthcare.